Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.

Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – such as diabetes and heart disease - whose treatment was disrupted when they fled.

A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.

Bringing healthcare closer to where people live, work and shop can effectively tackle hypertension – the most deadly noncommunicable disease.

Novartis opens up a path of research to protect proteins that guard against cancer.

Low- and middle-income countries will account for some three in four of the world’s cancer deaths within the next decade without better access to care. It’s a gap Amy Israel and her team at Novartis are trying to bridge.

New head of oncology research hopes to build on recent advances, explore new therapeutic approaches and beat certain cancers for good.

Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model